After more than two years of work, the US Food and Drug Administration is ready to formally begin its reorganization of the Office of New Drugs, which could cause signatory authority and other changes for sponsors with pending applications.
The agency announced on 26 September that Congress has approved the reorganization plan that will shift OND to a more...








